XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Net income (loss) $ (4,801,660) $ (7,228,011)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization expense 2,108,051 1,974,194
Deferred tax expense 0 4,293,963
Share-based compensation 1,005,239 849,198
Excess tax (benefit) expense derived from exercise of stock options 0 (91,109)
Noncash interest expense 44,117 60,708
Noncash investment gains (131,652) (48,084)
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable 1,339,974 124,748
Inventories 311,419 (485,739)
Other current assets and other assets 966,817 (428,176)
Accounts payable and other current liabilities (1,595,243) 640,453
Other long-term liabilities 142,486 239,703
Net cash provided by (used in) operating activities (610,452) (98,152)
Cash flows from investing activities:    
Additions to property and equipment (171,731) (172,899)
Purchases of marketable securities (20,851,951) (2,029,414)
Proceeds from sale of marketable securities 16,122,376 9,644,592
Additions to intangible assets (1,411,710) (841,647)
Net cash (used in) provided by investing activities (6,313,016) 6,600,632
Cash flows from financing activities:    
Borrowings on line of credit 36,000,000 14,700,000
Repayments on line of credit (33,800,000) (10,800,000)
Proceeds from sales of common stock, net of offering costs 200,909 0
Payments of deferred offering costs (248,108) 0
Repurchase of common shares (2,382,968) (2,893,857)
Net cash provided by (used in) financing activities (230,167) 1,006,143
Net increase (decrease) in cash and cash equivalents (7,153,635) 7,508,623
Cash and cash equivalents at beginning of period 45,412,868 34,510,330
Cash and cash equivalents at end of period $ 38,259,233 $ 42,018,953